Luminex's recent decision to reduce its workforce by 5 percent, close an office in Australia, and seek a buyer for its newborn screening business, was in part influenced by its attempt to obtain US regulatory clearance for its NeoPlex4 test, according to the firm's CEO.

Luminex's NeoPlex4 assay is based on the firm's xMAP bead array technology and tests for four analytes related to congenital hypothyroidism, congenital adrenal hyperplasia, and cystic fibrosis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.